BeiGene Ltd Strikes Exclusive Global License Deal with Ensem Therapeutics for CDK2 Inhibitor
China-based biopharmaceutical company BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced a licensing...
Cancer
Fosun Pharmaceutical’s FCN-437c filing Accepted for Review by China’s NMPA
Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196; SHA: 600196) has announced that the National...
CSPC Pharmaceutical’s Glumetinib Earns Breakthrough Therapy Designation in China
Glumetinib, a MET targeted tyrosine kinase inhibitor (TKI) co-developed by CSPC Pharmaceutical Group Ltd (HKG:...
Medilink Therapeutics’ YL201 Earns Orphan Drug Designation for Esophageal Cancer
Suzhou-based Medilink Therapeutics has announced that it has obtained orphan drug designation (ODD) from the...
BeiGene’s Brukinsa Secures Additional EU Approval for Follicular Lymphoma Treatment
BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has achieved its latest global approval for...
Usynova Pharmaceuticals Inks Licensing Deal with AstraZeneca for KRASG12D Inhibitor UA022
Shanghai-based Usynova Pharmaceuticals Ltd has announced a licensing agreement with UK pharmaceutical major AstraZeneca (AZ,...
Ascentage Pharma Secures Additional Indication Approval for Olverembatinib from NMPA
China-based Ascentage Pharma (HKG: 6855) has announced receiving another indication approval from the National Medical...
Apollomics’ Partner Avistone Wins Conditional Approval for c-Met Inhibitor in China
US-based biotech Apollomics Inc., (NASDAQ: APLM) has announced that its Chinese partner, Avistone Biotechnology Co.,...
Fosun Pharmaceutical Secures Clinical Trial Approvals for VT-101 in China and the US
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) has announced receiving clinical trial approvals for...
Baheal Pharmaceutical Group Enters Commercialization Partnership with Guangdong Ruidio Technology
China-based health services and distribution giant Baheal Pharmaceutical Group has struck a commercialization partnership with...
Pfizer and Astellas Pharma Secure FDA Approval for Xtandi in High-Risk Non-Metastatic Prostate Cancer
Partners Pfizer (NYSE: PFE) and Astellas Pharma (TSE: 4503) last week received indication extension approval...
AstraZeneca Receives FDA Approval for Truqap in HR-Positive, HER2-Negative Breast Cancer
UK-based pharmaceutical company AstraZeneca (AZ; NASDAQ: AZN) announced last week that it has received regulatory...
Alphamab Oncology’s JSKN003 ADC: Promising Preliminary Data in Advanced Solid Tumors
Alphamab Oncology (HKG: 9966) has released preliminary data from a Phase I clinical study on...
BMS’s Augtyro Receives FDA Approval for ROS1-Positive NSCLC
The US Food and Drug Administration (FDA) has granted Bristol Myers Squibb (BMS, NYSE: BMY)...
Astellas Pharma Acquires Propella Therapeutics for $175 Million to Boost Prostate Cancer Treatment
Japan’s Astellas Pharma (TYO: 4503) has announced the negotiation of a purchase agreement for US...
Eli Lilly Clears Final Regulatory Hurdle with NRC Approval for Point Biopharma Acquisition
The Nuclear Regulatory Commission (NRC) of the US has given its approval for the transfer...
Merck KGaA Outlines Expansion Plans for US Healthcare Market with Anticipated 2025 Drug Launches
Germany’s Merck KGaA (ETR: MRK), a leading player in the global pharmaceutical industry, has this...
EMA’s CHMP Issues Positive Opinion for Roche’s Tecentriq SC Subcutaneous Formulation
The Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA)...
Novartis Pharma AG Partners with Legend Biotech Corp. for CAR-T Therapies in $1.1 Billion Deal
China-based Legend Biotech Corp., (NASDAQ: LEGN) has secured a second multinational partnership for its chimeric...
BMS Secures ORM-6151 for Acute Myeloid Leukemia Treatment with Orum Therapeutics Deal
Bristol Myers Squibb (BMS; NYSE: BMY) has made a significant move in the field of...